Trends in drug discovery and in life sciences investing may be leading to lasting changes in both the investment models for venture capital firms and the business models for biopharmaceutical companies. The panel will explore to what extent these trends, and the changes they may lead to, are cyclical or more fundamental.



Objectives:

Review recent trends in life sciences VC investing and current areas of focus.

Analyze these current areas of focus including NRDO companies and "project financing" whereby infrastructure is kept to a minimum until enough de-risking has taken place.

Discuss how some of these new models/trends may affect life sciences venture capital returns in current and upcoming vintage years.